Blood sample analyzer, blood sample analysis method and computer-readable storage medium

Abstract

A blood sample analyzer, a blood sample analysis method and a computer-readable storage medium. The temperature of a temperature control assembly (12) of the blood sample analyzer reaches a first preset threshold value, and a sample liquid to be tested in the temperature control assembly (12) is slowly injected into a sheath flow assembly (13) at a preset speed, such that said sample liquid is heated for different time periods in the temperature control assembly (12); the sheath flow assembly (13) is used for acquiring a pulse signal when said sample liquid passes through a test region of the sheath flow assembly (13); and a processor (14) is used for calculating the counting stability of said sample liquid on the basis of the pulse signal and obtaining a test result of said sample liquid on the basis of the counting stability. Said sample liquid in the temperature control assembly (12) is injected into the sheath flow assembly (13), and the heating temperature and the heating time for said sample liquid are gradually increased, such that when cell aggregation has occurred in said sample liquid, disaggregation can be gradually performed at a preset temperature, so as to allow the processor (14) to determine, on the basis of the counting stability of said sample liquid, whether cell aggregation has occurred in said sample liquid and to obtain a corresponding test result, thus improving the determination precision of blood sample analyzers on cell aggregation, and further improving the counting accuracy of blood sample analyzers.

Description

Blood sample analyzer, blood sample analysis method, and computer-readable storage medium

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese patent application No. 202410392548.9, filed on March 29, 2024, entitled “Blood Sample Analyzer and Blood Sample Analysis Method,” the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present application relates to the field of medical device technology, and in particular to a blood sample analyzer, a blood sample analysis method, and a computer-readable storage medium. Background Art

[0004] Existing blood analyzers are used to analyze and test blood samples and obtain counts of blood or blood cell components, such as red blood cells, white blood cells, platelets, and hemoglobin. When performing blood cell counts, if the sample contains abnormal cold agglutinin levels or the blood collection process is not standardized, cells uniformly suspended in the blood may aggregate, causing cell agglutination and interfering with the blood analysis results.

[0005] Agglutinated cells can include red blood cells, white blood cells, and platelets, among others. For example, when red blood cell agglutination occurs, existing blood sample analyzers typically use the matching relationship between red blood cell and hemoglobin concentrations to determine whether the red blood cells are agglutinated and issue an alarm. Specifically, red blood cell agglutination is determined when the mean corpuscular hemoglobin content (MCH) or mean corpuscular hemoglobin concentration (MCHC) is above a predetermined reference range. However, for different sample types, such as those with high or low pigmentation, the mean corpuscular hemoglobin concentration often differs from the normal reference range, making it easy for blood sample analyzers to falsely alarm for red blood cell agglutination, resulting in low accuracy. Summary of the Invention

[0006] To solve the above technical problems, the present application provides a blood sample analyzer, a blood sample analysis method and a computer-readable storage medium.

[0007] In order to solve the above problems, the present application provides a first technical solution: a blood sample analyzer is provided, which includes a reaction component, a temperature control component, a sheath flow component and a processor. The reaction component is used to store and transport the sample liquid to be tested; one end of the temperature control component is connected to the reaction component through a pipeline, and the temperature control component is used to store the sample liquid to be tested; the other end of the temperature control component is connected to the sheath flow component through the pipeline, and the temperature of the temperature control component reaches a first preset threshold, and the sample liquid to be tested in the temperature control component is pushed into the sheath flow component, and the sheath flow component is used to obtain a pulse signal when the sample liquid to be tested passes through the detection area of ​​the sheath flow component; the processor is connected to the sheath flow component, and the processor is used to calculate the counting stability of the sample liquid to be tested based on the pulse signal, and obtain the detection result of the sample liquid to be tested based on the counting stability.

[0008] Optionally, the sample liquid to be tested in the above-mentioned temperature control component is pushed into the above-mentioned sheath flow component, so that the temperature of the sample liquid to be tested entering the above-mentioned sheath flow component changes with the pushing time of the sample liquid to be tested; the above-mentioned processor is used to calculate the particle data of the red blood cells flowing through the above-mentioned detection area in the first time period based on the above-mentioned pulse signal, and the above-mentioned processor is also used to perform linear regression analysis on the above-mentioned particle data to calculate the above-mentioned counting stability.

[0009] Optionally, the processor is further configured to: determine that red blood cell agglutination occurs in the sample liquid to be tested in response to the counting stability being greater than or equal to a second preset threshold; control the sheath flow component to extend the detection time of the sample liquid to be tested to obtain the particle data within a second time period; and obtain the detection result of the sample liquid to be tested based on the particle data within the second time period.

[0010] Optionally, the processor is configured to use the particle data within the second time period as a detection result of the sample liquid to be tested.

[0011] Optionally, the processor is used to add the particle data in the second time period and the particle data in the first time period based on a preset weight parameter, and to compensate the summed result with the particle data in the second time period to calculate the detection result of the sample liquid to be tested.

[0012] Optionally, the processor is further configured to: in response to the counting stability being greater than a third preset threshold, select particle data of an extended time period away from the first time period as particle data of the second time period, the third preset threshold being greater than the second preset threshold; and in response to the counting stability being less than the third preset threshold, select particle data of an extended time period close to the first time period as particle data of the second time period.

[0013] Optionally, the processor is configured to perform linear regression analysis on the particle data to obtain a linear function of the particle data and the detection time of the sample liquid to be tested, and the processor is further configured to use the slope of the linear function as the counting stability.

[0014] Optionally, the processor is configured to calculate a counting result of the sample liquid to be tested when it is determined that red blood cells are agglutinated based on the intercept of the linear function.

[0015] Optionally, the temperature control component includes a sample chamber and a heating element, one end of the sample chamber is connected to the reaction component through the pipeline, and the other end of the sample chamber is connected to the sheath flow component through the pipeline. The heating element is arranged in the sample chamber and connected to the processor, and the heating element is used to heat the sample chamber.

[0016] Optionally, the reaction component is used to mix the blood sample and the detection reagent to obtain the sample liquid to be tested. The blood sample analyzer also includes a sample pushing component, which is connected to the reaction component through the pipeline. The sample pushing component is used to push the sample liquid to be tested in the reaction component to the sample chamber. The processor is used to start the heating element so that the heating element heats the sample chamber to the first preset threshold value.

[0017] Optionally, the reaction component is used to mix the blood sample and the detection reagent within a third time period to obtain the sample liquid to be tested, and the processor is used to start the heating element so that the heating element heats the sample chamber for a fourth time period, wherein the third time period at least partially overlaps with the fourth time period.

[0018] Optionally, the time point at which the reaction of the reaction component is completed is the same as the time point at which the heating of the sample chamber is completed.

[0019] Optionally, the time point when the sample liquid to be tested is pushed into the sample chamber is the same as the time point when the heating of the sample chamber is completed.

[0020] Optionally, after the heating element heats the sample chamber to the first preset threshold, the processor is used to wait for the sample liquid to be tested in the sample chamber to be depolymerized and incubated for a preset time before controlling the sample pushing component to push the sample liquid to be tested in the sample chamber to the sheath flow component.

[0021] Optionally, the above-mentioned blood sample analyzer also includes a waste liquid component, which is connected to the above-mentioned sheath flow component through the above-mentioned pipeline. The above-mentioned sample liquid to be tested flowing through the above-mentioned detection area will enter the above-mentioned waste liquid component through the above-mentioned pipeline. The above-mentioned waste liquid component is used to collect and store the detection waste liquid generated during the detection process of the above-mentioned sheath flow component.

[0022] To solve the above problems, the present application provides a second technical solution: providing a blood sample analysis method, including: controlling a temperature control component to heat the sample liquid to be tested; in response to the temperature of the above temperature control component reaching a first preset threshold, pushing the sample liquid to be tested in the above temperature control component into the above sheath flow component, so that the above sample liquid to be tested passes through the detection area of ​​the above sheath flow component and generates a pulse signal; calculating the counting stability of the above sample liquid to be tested based on the above pulse signal, and obtaining the detection result of the above sample liquid to be tested based on the above counting stability.

[0023] Optionally, the counting stability of the sample liquid to be tested is calculated based on the pulse signal, and the detection result of the sample liquid to be tested is obtained based on the counting stability, including: calculating the particle data of the red blood cells flowing through the detection area in the first time period based on the pulse signal; performing linear regression analysis on the particle data to calculate the counting stability.

[0024] Optionally, after the step of performing linear regression analysis on the particle data to calculate the counting stability, the blood sample analysis method further includes: in response to the counting stability being greater than a second preset threshold, determining that red blood cell agglutination occurs in the sample liquid to be tested; controlling the sheath flow component to extend the detection time of the sample liquid to be tested to obtain particle data within a second time period; and obtaining the detection result of the sample liquid to be tested based on the particle data within the second time period.

[0025] Optionally, the above-mentioned control of the above-mentioned sheath flow component extends the detection time of the above-mentioned sample liquid to be tested to obtain particle data within the second time period, including: in response to the above-mentioned counting stability being greater than or equal to a third preset threshold, selecting the particle data of the extended time period away from the above-mentioned first time period as the particle data of the above-mentioned second time period; in response to the counting stability being less than the above-mentioned third preset threshold, selecting the above-mentioned particle data of the extended time period close to the above-mentioned first time period as the particle data of the above-mentioned second time period; wherein the above-mentioned third preset threshold is greater than the above-mentioned second preset threshold.

[0026] To solve the above problem, the present application provides a third technical solution: providing a computer-readable storage medium, wherein the computer-readable storage medium stores program instructions, and the program instructions can be executed by a processor to implement the above blood sample analysis method.

[0027] The present application provides a blood sample analyzer, a blood sample analysis method, and a computer-readable storage medium. The blood sample analyzer includes a reaction component, a temperature control component, a sheath flow component, and a processor. The reaction component is used to store and transport a sample liquid to be tested; one end of the temperature control component is connected to the reaction component via a pipeline, and the temperature control component is used to store the sample liquid to be tested; the other end of the temperature control component is connected to the sheath flow component via a pipeline. When the temperature of the temperature control component reaches a first preset threshold, the sample liquid to be tested in the temperature control component is pushed into the sheath flow component, and the sheath flow component is used to obtain a pulse signal when the sample liquid to be tested passes through a detection area of ​​the sheath flow component; the processor is connected to the sheath flow component, and the processor is used to calculate the counting stability of the sample liquid to be tested based on the pulse signal, and obtain a detection result of the sample liquid to be tested based on the counting stability. Through the above method, when the sample liquid to be tested in the temperature control component is pushed into the sheath flow component, the heating temperature and heating time of the sample liquid to be tested are gradually increased, so that when cells aggregate in the sample liquid to be tested, they can be gradually disaggregated at a preset temperature, so that the processor can judge whether cells aggregate in the sample liquid to be tested based on the counting stability of the sample liquid to be tested and obtain corresponding test results, thereby improving the judgment accuracy of the blood sample analyzer for cell agglutination and thus improving the counting accuracy of the blood sample analyzer. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0029] FIG1 is a schematic structural diagram of an embodiment of a blood sample analyzer provided by the present application;

[0030] FIG2 is a diagram showing particle flow changes in a first embodiment of a sample solution to be tested provided by the present application;

[0031] FIG3 is a diagram showing particle flow changes in a second embodiment of a sample solution to be tested provided by the present application;

[0032] FIG4 is a flow chart of an embodiment of a blood sample analysis method provided by the present application;

[0033] FIG5 is a schematic structural diagram of an embodiment of a computer-readable storage medium provided in the present application. Modes for Carrying Out the Invention

[0034] The present application will be further described in detail below in conjunction with the accompanying drawings and examples. It is particularly noted that the following examples are only intended to illustrate the present application and are not intended to limit the scope of the present application. Similarly, the following examples are only some examples of the present application and not all examples. All other examples obtained by those of ordinary skill in the art without creative work are intended to fall within the scope of protection of this application.

[0035] It should be noted that if the embodiments of the present application involve directional indications (such as up, down, left, right, front, back, etc.), such directional indications are only used to explain the relative position relationship, movement status, etc. between the various components under a certain specific posture (as shown in the accompanying drawings). If the specific posture changes, the directional indication will also change accordingly.

[0036] In addition, if there are descriptions involving "first", "second", etc. in the embodiments of the present application, the descriptions of "first", "second", etc. are only for descriptive purposes and cannot be understood as indicating or implying their relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include at least one of such features. In addition, the technical solutions between the various embodiments can be combined with each other, but they must be based on the fact that they can be implemented by ordinary technicians in this field. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such a combination of technical solutions does not exist and is not within the scope of protection required by this application.

[0037] Understandably, when performing a red blood cell count test on existing blood analyzers, if the sample contains abnormal cold agglutinin levels or the blood collection process is not standardized, the red blood cells uniformly suspended in the blood may clump together. Because red blood cell agglutination caused by cold agglutinins can be observed as a clinical indication, blood analyzers typically issue an alarm when they detect cell agglutination in the sample.

[0038] Existing blood sample analyzers typically use the matching relationship between red blood cell and hemoglobin concentrations to determine whether red blood cells are agglutinated and issue an alarm. For example, existing blood sample analyzers can provide a red blood cell agglutination alarm when the mean corpuscular hemoglobin content (MCH) or mean corpuscular hemoglobin concentration (MCHC) is above a predetermined reference range. However, for hypochromic samples, when the sample is not agglutinated, the MCHC value is lower than the normal reference range. When the sample agglutinates, the MCHC value rises but remains within the normal reference range, resulting in an inability to issue an agglutination alarm. For hyperchromic samples, the MCHC value is already higher than the normal reference range, making it easy to be judged as a mismatch between red blood cells and hemoglobin, thereby falsely alarming for red blood cell agglutination. This results in the blood sample analyzer being unable to accurately identify samples with cell agglutination, and the counting accuracy is reduced.

[0039] Because samples with aggregated red blood cells (RBCs) show a higher particle count under optical detection than under impedance detection, existing blood sample analyzers can determine whether RBCs are aggregated by performing both an impedance test and an optical test, comparing the two measurement results for deviation. However, this method requires both optical and impedance testing, placing high demands on the analyzer's hardware, increasing the complexity of the test process, and reducing the efficiency of counting and analysis.

[0040] In view of this, the present application first provides a blood sample analyzer. See Figure 1, which is a schematic diagram of the structure of one embodiment of the blood sample analyzer provided by the present application. As shown in Figure 1, the blood sample analyzer includes a reaction component (not shown), a temperature control component 12, a sheath flow component 13, and a processor 14.

[0041] The reaction assembly is used to store and transport the sample liquid to be tested. One end of the temperature control assembly 12 is connected to the reaction assembly via a pipeline, and the other end of the temperature control assembly 12 is connected to the sheath flow assembly via a pipeline. The temperature control assembly 12 is used to store the sample liquid to be tested. When the temperature of the temperature control assembly 12 reaches a first preset threshold, the sample liquid to be tested in the temperature control assembly 12 is pushed into the sheath flow assembly 13. The sheath flow assembly 13 is used to obtain a pulse signal when the sample liquid to be tested passes through the detection area of ​​the sheath flow assembly 13. The processor 14 is connected to the sheath flow assembly 13 and is used to calculate the counting stability of the sample liquid to be tested based on the pulse signal and obtain a detection result of the sample liquid to be tested based on the counting stability.

[0042] Specifically, the blood sample analyzer can be used to obtain a blood sample and a detection reagent. The reaction component is used to mix and react the blood sample and the detection reagent to obtain a sample liquid to be tested. The sample liquid to be tested can be transported to the temperature control pipeline through the pipeline between the reaction component and the temperature control component 12. The temperature control pipeline may include a sample chamber 121 and a heating element 122. The sample chamber 121 is used to store the sample liquid to be tested delivered by the reaction component. The heating element 122 is used to heat the sample chamber 121 to increase the temperature of the temperature control component 12 and maintain it at a first preset threshold. In the event that cell agglutination occurs in the sample liquid to be tested, the temperature control component 12 is used to heat and incubate the agglutinated cells in the sample liquid to be tested so that the agglutinated cells disaggregate at the temperature of the first preset threshold.

[0043] When the temperature of the temperature control assembly 12 reaches a first preset threshold, the sample liquid in the temperature control assembly 12 is slowly pushed into the sheath flow assembly 13 at a preset speed, so that the sample liquid is heated for different periods of time in the temperature control assembly 12, and the temperature of the sample liquid entering the sheath flow assembly 13 slowly increases with the increase in the pushing time. It can be understood that the temperature control assembly 12 includes at least a first section of sample liquid that is first pushed into the sheath flow assembly 13 and a second section of sample liquid that is later pushed into the sheath flow assembly 13. The heating time of the first section of sample liquid in the temperature control assembly 12 is shorter than the heating time of the second section of sample liquid. When cell aggregation occurs in the sample liquid, the first section of sample liquid undergoes disaggregation in the temperature control assembly 12 for a shorter period than the second section of sample liquid. The degree of cell aggregation of the first section of sample liquid upon entering the sheath flow assembly 13 is greater than that of the second section of sample liquid.

[0044] The sheath flow assembly 13 is configured to obtain pulse signals when the first and second sections of the sample to be tested pass through the detection zone of the sheath flow assembly 13. The processor 14 is configured to calculate count stability based on the pulse signals of the first and second sections of the sample to be tested. When the count stability of the first and second sections of the sample to be tested is lower than a preset threshold, it indicates that the count results of the first and second sections of the sample to be tested are similar, there is no cell agglutination or the number of cell agglutinations in the first and second sections of the sample to be tested is small, the particle data of the first and second sections of the sample to be tested should be relatively close, and the count stability is low. When the count stability of the first and second sections of the sample to be tested is higher than the preset threshold, it indicates that the count results of the first and second sections of the sample to be tested are significantly different, the degree of cell agglutination in the first and second sections of the sample to be tested is different, the sample liquid to be tested has undergone different degrees of disaggregation in the temperature control assembly 12, the particle data of the first and second sections of the sample to be tested should be significantly different, and the count stability is high. Therefore, the processor 14 can determine whether cell agglutination occurs in the sample solution to be tested based on the counting stability, and obtain a corresponding test result.

[0045] In alternative embodiments, the processor 14 may be referred to as a CPU (Central Processing Unit); the processor 14 may also be an electronic chip with signal processing capabilities; the processor 14 may also be a general-purpose processor 14, a digital signal processor 14 (DSP), an application-specific integrated circuit (ASIC), a field-programmable gate array (FPGA), or other programmable logic device, discrete gate or transistor logic device, or discrete hardware component. The general-purpose processor 14 includes, but is not limited to, a microprocessor 14 or a conventional processor 14.

[0046] In the embodiment of the present application, through the above-mentioned method, when the sample liquid to be tested in the temperature control component 12 is pushed into the sheath flow component 13, the heating temperature and heating time of the sample liquid to be tested are gradually increased, so that when cells aggregate in the sample liquid to be tested, they can be gradually disaggregated at a preset temperature, so that the processor 14 can judge whether cells aggregate in the sample liquid to be tested based on the counting stability of the sample liquid to be tested and obtain corresponding test results, thereby improving the judgment accuracy of the blood sample analyzer for cell agglutination, and thus improving the counting accuracy of the blood sample analyzer.

[0047] In one embodiment, the sample liquid in the temperature control assembly 12 is pushed into the sheath flow assembly 13, such that the temperature of the sample liquid entering the sheath flow assembly 13 varies with the time the sample liquid is pushed into the sheath flow assembly 13. The processor 14 is configured to calculate particle data of red blood cells flowing through the detection zone during a first time period based on the pulse signal. The processor 14 is also configured to perform linear regression analysis on the particle data to calculate count stability.

[0048] Specifically, as the sample liquid to be tested in the temperature control component 12 is pushed into the sheath flow component 13, the temperature of the sample liquid to be tested in the sheath flow component 13 increases as the pushing time increases, so that the agglutinated cells in the sample to be tested that is pushed in first are disaggregated at a temperature of a first preset threshold. The sheath flow component 13 is used to obtain a corresponding pulse signal when the sample liquid to be tested passes through the detection zone during a first time period, and the processor 14 is used to calculate the particle data of the red blood cells at the corresponding moment based on the pulse signal. The processor 14 is also used to perform a linear regression analysis on the particle data. For example, a linear regression analysis is performed with the detection time as the independent variable and the number of red blood cell particles as the dependent variable to determine the quantitative relationship between the independent variable and the dependent variable and obtain the counting stability of the sample liquid to be tested during the first time period.

[0049] In this embodiment, the sample liquid to be tested is a sample flow arranged in a single cell. When the sample liquid to be tested flows through the detection area of ​​the sheath flow component 13, since the blood cells in the sample liquid to be tested are poor conductors, the blood cells will cause the pulse signal near the detection area to change when passing through the detection area, thereby enabling the processor 14 to count the red blood cells flowing through the detection area in the first time period based on the pulse signal and obtain particle data.

[0050] In the above manner, the blood sample analyzer of this embodiment can calculate the particle data of the red blood cells flowing through the detection area during the first time period through the processor 14, and perform linear regression analysis on the particle data to calculate the counting stability, so that the processor 14 can determine whether cell aggregation occurs in the sample liquid to be tested based on the counting stability of the sample liquid to be tested and obtain corresponding test results, thereby improving the judgment accuracy of the blood sample analyzer for cell agglutination and further improving the counting accuracy of the blood sample analyzer.

[0051] Optionally, the processor 14 is also used to: in response to the counting stability being greater than a second preset threshold, determine that red blood cell agglutination occurs in the sample liquid to be tested; control the sheath flow component 13 to extend the detection time of the sample liquid to be tested to obtain particle data within a second time period; and obtain the detection result of the sample liquid to be tested based on the particle data within the second time period.

[0052] Specifically, with the detection time as the independent variable and the number of red blood cell particles as the dependent variable, the ordinate represents the particle data, and the abscissa represents the time, with a unit of 100ms; a particle flow change diagram of the test sample liquid during the sheath flow detection process can be obtained. Please refer to Figures 2 and 3. Figure 2 is a particle flow change diagram of the first embodiment of the test sample liquid provided by the present application, and Figure 3 is a particle flow change diagram of the second embodiment of the test sample liquid provided by the present application. As shown in Figure 2, Figure 2 is a particle flow change diagram of the test sample liquid during the sheath flow detection process when red blood cell agglutination occurs. As the detection time increases, the degree of red blood cell disaggregation in the test sample liquid pushed into the sheath flow component 13 increases, so that the particle data of the red blood cells in an initial time period increases with the increase in detection time; when the red blood cell disaggregation in the test sample liquid is completed or is close to completion, the particle data in the test sample liquid will tend to be stable in the subsequent detection time. As shown in FIG3 , FIG3 is a particle flow change diagram of the non-erythrocyte agglutination test sample liquid during the sheath flow detection process. The particle data of the non-erythrocyte agglutination test sample liquid during the sheath flow detection process generally tends to be stable.

[0053] Through the above steps, the processor 14 of this embodiment can calculate the count stability based on the linear regression analysis of the particle data and determine whether erythrocyte agglutination has occurred in the test sample liquid. When the count stability is greater than a second preset threshold, for example, when the count stability is greater than 1, and the particle data of the test sample liquid tilts over time, the processor 14 can determine that erythrocyte agglutination has occurred in the test sample liquid. The greater the count stability, the higher the degree of erythrocyte agglutination in the test sample liquid. The processor 14 is further configured to control the sheath flow assembly 13 to extend the detection time of the test sample liquid in response to erythrocyte agglutination in the test sample liquid to obtain particle data for a second time period. The second time period is a time series that occurs after the first time period during the process of the sheath flow assembly 13 detecting the test sample liquid. It is understood that after a period of disaggregation incubation, the degree of disaggregation in the test sample liquid in the second time period is generally higher than that in the first time period, allowing the processor 14 to obtain a test result for the test sample liquid based on the particle data in the second time period.

[0054] In a possible implementation, after obtaining the particle data in the second time period, the processor 14 can directly use the particle data in the second time period as the detection result of the sample liquid to be tested, or it can add the particle data in the second time period with the particle data in the first time period based on a preset weight parameter, and compensate the result of the addition by the particle data in the second time period to calculate the detection result of the sample liquid to be tested; the user can make a choice based on the actual computing power requirements or the degree of agglutination of the sample liquid to be tested, and no specific limitation is made here.

[0055] In an embodiment of the present application, the processor 14 is used to determine that red blood cell agglutination occurs in the sample liquid to be tested in response to the counting stability being greater than a second preset threshold value, and to control the sheath flow component 13 to extend the detection time of the sample liquid to be tested to obtain particle data within a second time period, so that the processor 14 can obtain the detection result of the sample liquid to be tested based on the particle data within the second time period, thereby improving the judgment accuracy of the blood sample analyzer for red blood cell agglutination, and thereby improving the counting accuracy of the blood sample analyzer.

[0056] Furthermore, the processor 14 is further configured to: in response to the counting stability being greater than or equal to a third preset threshold, select particle data from an extended time period away from the first time period as particle data for the second time period; and in response to the counting stability being less than the third preset threshold, select particle data from an extended time period close to the first time period as particle data for the second time period, wherein the third preset threshold is greater than the second preset threshold.

[0057] Specifically, after the processor 14 calculates the counting stability of the test sample liquid within the first time period, in one embodiment, if the counting stability is greater than or equal to a third preset threshold value, i.e., the degree of agglutination of the test sample liquid is high, resulting in significant changes in the particle data during the disaggregation process, the processor 14 is further configured to select the particle data for an extended time period away from the first time period as the particle data for the second time period. Exemplarily, the extended time period away from the first time period may be a counting time between n-1 times and n times the first time period. For example, when the first time period is the detection time of the test sample liquid between 0 and 9 seconds and n=3, the extended time period may be 18 seconds to 27 seconds. Alternatively, the extended time period away from the first time period may be a time period that is significantly longer than the first time period of 0 to 9 seconds, without further specific limitations.

[0058] Alternatively, in another embodiment, if the counting stability is less than a third preset threshold, i.e., a certain degree of cell agglutination occurs in the test sample liquid but the degree of agglutination is low, the processor 14 may be configured to select particle data from an extended time period close to the first time period as particle data for the second time period. Specifically, the extended time period close to the first time period may be a time period during which continuous sheath flow detection is performed after the first time period. Exemplarily, the extended time period close to the first time period may be a counting time between n-1 times and n times the first time period. For example, when the first time period is a detection time of the test sample liquid between 0 and 9 seconds and n=2, the extended time period may be 10 seconds to 18 seconds. Alternatively, the extended time period close to the first time period may be a time period with a shorter detection time relative to the first time period of 0 to 9 seconds, which is not specifically limited herein.

[0059] In an embodiment of the present application, the processor 14 of this embodiment can determine the degree of agglutination of the sample liquid to be tested by judging the relationship between the counting stability and the third preset threshold value, so that the processor 14 can select a relatively later extended time period to perform cell counting and obtain test results when the degree of agglutination is high, thereby extending the disaggregation incubation time of the agglutinated cells and improving the counting accuracy of the blood sample analysis; the processor 14 can also select a relatively earlier extended time period to perform cell counting and obtain test results when the degree of agglutination is low, thereby reducing the time consumed in disaggregation and improving the detection efficiency of the blood sample analyzer.

[0060] Optionally, the processor 14 is configured to perform linear regression analysis on the particle data to obtain a linear function of the particle data and the detection time of the sample liquid to be tested. The processor 14 is further configured to use the slope of the linear function as the counting stability.

[0061] Specifically, the processor 14 can perform linear fitting on the particle data of red blood cells flowing through the detection area during the first time period by linear regression analysis to calculate the expression of the linear function of the fitting straight line, and analyze the counting stability of the particle data by the slope of the linear function.

[0062] For example, assuming that the processor 14 obtains a total of 90 particle data of the sample liquid to be tested within 9 seconds, the number of particles in the particle data is used as the dependent variable y=[y1, y2…, y90], and the time unit in the particle data is used as the independent variable x=1-90, the processor 14 can calculate the counting stability using the linear regression analysis method as follows:

[0063] Step S1: Calculate the mean of x and y as x_mean and y_mean.

[0064] Step S2: Calculate the deviation values ​​of x and y, that is, subtract the mean from each value of x and y to obtain new arrays x_dev and y_dev.

[0065] Among them, x_dev = [x1-x_mean, x2-x_mean…,x3-x_mean];

[0066] y_dev = [y1-y_mean, y2-y_mean…,y3-y_mean];

[0067] Step S3: Calculate the slope K using the following formula: K = Σ(x_dev * y_dev) / Σ(x_dev * x_dev). This means K is equal to the sum of the products of x_dev and y_dev divided by the sum of the squares of x_dev. K, as the slope of the fitted line, represents the counting stability of the measured particle flow.

[0068] Step S4: Calculate the intercept B using the following formula: B = y_mean - K * x_mean, where B is equal to the mean of y minus the slope K multiplied by the mean of x.

[0069] Step S5: The linear function expression is calculated as y = K * x + B, where K can be used to represent the counting stability of the particle data, and B can be used to measure the initial concentration of the sample liquid to be tested.

[0070] In an embodiment of the present application, the processor 14 is used to calculate a linear function of particle data and the detection time of the sample liquid to be tested through linear regression analysis, and use the slope of the linear function as the counting stability, so that the processor 14 can determine whether red blood cell aggregation occurs in the sample liquid to be tested based on the counting stability of the sample liquid to be tested and obtain corresponding test results, thereby improving the judgment accuracy of the blood sample analyzer for cell agglutination, and thereby improving the counting accuracy of the blood sample analyzer.

[0071] Furthermore, the processor 14 is configured to calculate the counting result of the sample liquid to be tested when it is determined that red blood cells are agglutinated based on the intercept of the linear function.

[0072] Specifically, after obtaining the linear function of the particle data, the processor 14 can calculate the counting result of the sample liquid to be tested before disaggregation through the intercept B of the linear function, so that the user or the processor 14 can measure the disaggregation degree of the sample liquid to be tested through the intercept B, so that the user can intuitively observe the disaggregation process of the sample liquid to be tested through the measured data, and is beneficial for the user to observe the cell agglutination index of the sample liquid to be tested in clinical application scenarios, thereby improving the user's usage experience.

[0073] In one embodiment, the temperature control component 12 includes a sample chamber 121 and a heating element 122. One end of the sample chamber 121 is connected to the reaction component through a pipeline, and the other end of the sample chamber 121 is connected to the sheath flow component 13 through a pipeline. The heating element 122 is arranged in the sample chamber 121 and connected to the processor 14. The heating element 122 is used to heat the sample chamber 121.

[0074] Specifically, the heating element 122 is disposed in the sample chamber 121 and connected to the processor 14. The heating element 122 is used to heat the sample chamber 121 so that the temperature of the sample chamber 121 reaches a first preset threshold. The sample chamber 121 is used to serve as a place to receive the sample liquid to be tested and to disaggregate and incubate the sample liquid to be tested at the temperature of the first preset threshold. The processor 14 can be used to control the heating process of the heating element 122 so that the sample chamber 121 can be stably heated and the agglutinated cells in the sample liquid to be tested can be separated within the sample chamber 121, thereby ensuring the temperature control stability of the temperature control component 12. The first preset threshold can be between 37°C and 45°C, for example, the first preset threshold can be between 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, or 45°C.

[0075] Optionally, in one embodiment, the reaction component is used to mix the blood sample and the detection reagent to obtain the sample liquid to be tested. The blood sample analyzer also includes a sample pushing component 16, which is connected to the reaction component through a pipeline. The sample pushing component 16 is used to push the sample liquid to be tested in the reaction component to the sample chamber 121, and the processor 14 is used to start the heating element 122 so that the heating element 122 heats the sample chamber 121 to a first preset threshold.

[0076] Specifically, the reaction assembly is used as a reaction site and allows the blood sample and the detection reagent to mix with each other to obtain the sample liquid to be tested. After the sample liquid to be tested is prepared, the processor 14 is used to control the sample pushing assembly 16 to push the sample liquid to be tested in the reaction assembly to the sample chamber 121. The processor 14 is also used to control the heating element 122 to heat the sample chamber 121 so that the temperature of the sample chamber 121 reaches a first preset threshold. After the temperature of the sample chamber 121 reaches the first preset threshold, the processor 14 is also used to control the sample pushing assembly 16 to push the sample liquid to be tested in the sample chamber 121 so that the sample liquid to be tested passes through the pipeline at a preset speed and is slowly pushed into the sheath flow assembly 13.

[0077] In an embodiment of the present application, the blood sample analyzer is used to heat the sample liquid to be tested in the reaction component after it has reacted completely and been pushed into the sample chamber 121, so that the sample liquid to be tested in the sample chamber 121 can be depolymerized during the heating process and the depolymerization waiting time is reduced, so that the processor 14 can select a time close to the first time period as an extended time period for counting and obtaining the test results, thereby improving the detection efficiency of the blood sample analysis.

[0078] Optionally, the reaction component is used to mix the blood sample and the detection reagent within a third time period to obtain the sample liquid to be tested, and the processor 14 is used to start the heating element 122 so that the heating element 122 heats the sample chamber 121 for a fourth time period, wherein the third time period and the fourth time period at least partially overlap.

[0079] Specifically, after adding the blood sample and detection reagent, the reaction component typically requires a period of reaction before the sample liquid to be tested is obtained. The time spent in the reaction component from adding the blood sample to obtaining the sample liquid to be tested is the third time period. The processor 14 is used to control the heater 122 to heat the sample chamber 121, so that the heating time spent in heating the sample chamber 121 from the initial temperature to the first preset threshold is the fourth time period. The third time period and the fourth time period of the blood sample analyzer of this embodiment at least partially overlap. That is, the processor 14 can control the heater 122 to heat the sample liquid while controlling the reaction component to react and prepare the sample, thereby reducing the time waiting for the reaction component to react.

[0080] Among them, the third time period and the fourth time period at least partially overlap, which may include: the processor 14 is used to control the time point when the reaction of the reaction component is completed to be the same as the time point when the heating of the sample chamber 121 is completed, so that the processor 14 can control the pushing component to push the sample liquid to be tested in the reaction component into the sample chamber 121 at a preset speed and push it into the sheath flow component 13 through the sample chamber 121; or, after the reaction component reaction is completed and the sample liquid to be tested is obtained, the processor 14 is used to control the time point when the sample liquid to be tested is pushed into the sample chamber 121 to be the same as the time point when the heating of the sample chamber 121 is completed, so that the processor 14 can control the pushing component to push the sample liquid to be tested in the sample chamber 121 into the sheath flow component 13 and perform sheath flow detection at the same time as the heating is completed.

[0081] In an embodiment of the present application, the processor 14 of the blood sample analyzer is used to heat the sample chamber 121 while the reaction component prepares the sample liquid to be tested, so as to reduce the reaction time waiting for the reaction component, so as to achieve efficient utilization of resources while taking into account the detection efficiency, thereby improving the detection efficiency of blood sample analysis.

[0082] Furthermore, after the processor 14 controls the heating element 122 to heat the sample chamber 121 to a first preset threshold value, the processor 14 can also be used to immediately control the sample pushing component 16 to push the sample liquid to be tested in the sample chamber 121 to the sheath flow component 13, or the processor 14 can also be used to wait for the sample liquid to be tested in the sample chamber 121 to be depolymerized and incubated for a preset time before controlling the sample pushing component 16 to push the sample liquid to be tested in the sample chamber 121 to the sheath flow component 13. The user can make a choice based on the degree of agglutination of the sample liquid to be tested or the requirements of detection efficiency, which is not specifically limited here.

[0083] In one embodiment, the blood sample analyzer also includes a waste liquid component 15, which is connected to the sheath flow component 13 through a pipeline. The sample liquid to be tested flowing through the detection area will enter the waste liquid component 15 through the pipeline. The waste liquid component 15 is used to collect and store the detection waste liquid generated during the sheath flow detection process.

[0084] The present application also proposes a blood sample analysis method. Please refer to Figure 4, which is a flow chart of an embodiment of the blood sample analysis method provided by the present application. As shown in Figure 4, the blood sample analysis method of this embodiment includes the following steps:

[0085] Step S11: controlling the temperature control component 12 to heat the sample liquid to be tested.

[0086] Specifically, the temperature control component 12 includes a sample chamber 121 and a heating element 122 . The sample chamber 121 is used to store the sample liquid to be tested. The heating element 122 is used to heat the sample chamber 121 so that the aggregated cells in the sample liquid to be tested are disaggregated and incubated at the heating temperature of the sample chamber 121 .

[0087] Step S12: In response to the temperature of the temperature control component 12 reaching a first preset threshold, the sample liquid in the temperature control component 12 is pushed into the sheath flow component 13, so that the sample liquid passes through the detection area of ​​the sheath flow component 13 and generates a pulse signal.

[0088] When the temperature of the temperature control assembly 12 reaches a first preset threshold, the sample pushing assembly 16 is controlled to push the sample liquid to be tested in the temperature control assembly 12 into the sheath flow assembly 13, so that the heated and incubated sample liquid to be tested passes through the detection zone of the sheath flow assembly 13 and generates a pulse signal. It is understandable that because the temperature control assembly 12 and the sheath flow assembly 13 are connected by a pipeline, when the sample pushing assembly 16 pushes the sample liquid to be tested in the temperature control assembly 12, the sample liquid to be tested located in front of the outlet of the sample chamber 121 is pushed into the pipeline first, and the sample liquid to be tested located behind the outlet of the sample chamber 121 is pushed into the pipeline later. The sample liquid to be tested at different pushing times undergoes different heating times within the sample chamber 121, and the sample liquid to be tested undergoes different degrees of disaggregation in the temperature control assembly 12. Therefore, the processor 14 can determine whether cell agglutination has occurred in the sample liquid to be tested based on the counting stability and obtain the corresponding detection result.

[0089] Step S13: calculating the counting stability of the sample liquid to be tested based on the pulse signal, and obtaining a detection result of the sample liquid to be tested based on the counting stability.

[0090] After obtaining the pulse signal generated when the sample liquid to be tested passes through the detection zone of the sheath flow component 13, the pulse signal within the first preset time period is summarized and analyzed, and the counting stability of the sample liquid to be tested is calculated. Since samples with cell agglutination undergo varying degrees of disaggregation, the particle data calculated from the pulse signal of the sample liquid to be tested will show a trend of change and increase to a certain extent. Therefore, the sample liquid to be tested can be determined to be a sample with cell agglutination by having a counting stability greater than or equal to a second preset threshold. Since samples without cell agglutination will not disaggregate after being heated and incubated by the temperature control component 12, the particle data of the sample liquid to be tested will generally tend to be stable. Therefore, the sample liquid to be tested can be determined to be a sample without cell agglutination by having a counting stability less than the second preset threshold. From the above analysis, it can be seen that the blood sample analysis method of the embodiment of the present application can determine cell agglutination by the change in the particle counting stability of the sample liquid to be tested during the detection process of the sheath flow component 13. The method is simple and easy to implement, and can effectively improve the accuracy of cell agglutination determination, thereby improving the counting accuracy of blood sample analysis.

[0091] Optionally, step S13 of the blood sample analysis method of this embodiment further includes: calculating particle data of red blood cells flowing through the detection area during the first time period based on the pulse signal; and performing linear regression analysis on the particle data to calculate counting stability.

[0092] Optionally, after the above-mentioned step of performing linear regression analysis on the particle data to calculate the counting stability, the blood sample analysis method of this embodiment also includes the following steps: in response to the counting stability being greater than a second preset threshold, determining that red blood cell agglutination occurs in the sample liquid to be tested; controlling the sheath flow component 13 to extend the detection time of the sample liquid to be tested to obtain particle data within a second time period; and obtaining the detection result of the sample liquid to be tested based on the particle data within the second time period.

[0093] Optionally, the step of controlling the sheath flow component 13 to extend the detection time of the sample liquid to be tested to obtain particle data within the second time period also includes the following steps: in response to the counting stability being greater than or equal to a third preset threshold, selecting particle data of an extended time period away from the first time period as particle data of the second time period; in response to the counting stability being less than the third preset threshold, selecting particle data of an extended time period close to the first time period as particle data of the second time period; wherein the third preset threshold is greater than the second preset threshold.

[0094] Please refer to Figure 5, which is a schematic diagram of the structure of an embodiment of a computer-readable storage medium provided by the present application. As shown in Figure 5, the computer-readable storage medium 110 stores program instructions 103 that can implement all the above methods.

[0095] If the integrated units of the functional units in the various embodiments of the present application are implemented in the form of software functional units and sold or used as independent products, they can be stored in a computer-readable storage medium 110. Based on this understanding, the technical solution of the present application, or the part that contributes to the prior art, or all or part of the technical solution can be embodied in the form of a software product. The computer-readable storage medium 110 includes a number of instructions in a program instruction 103 to enable a computer device (which can be a personal computer, a system server, or a network device, etc.), an electronic device (such as an MP3, MP4, etc., or a mobile terminal such as a mobile phone, a tablet computer, a wearable device, or a desktop computer, etc.) or a processor to execute all or part of the steps of the methods of the various embodiments of the present application.

[0096] Those skilled in the art will appreciate that the embodiments of the present application may be provided as methods, systems, or computer program products. Therefore, the present application may take the form of a complete hardware embodiment, a complete software embodiment, or an embodiment combining software and hardware. Furthermore, the present application may take the form of a computer program product implemented on one or more computer-readable storage media 110 (including but not limited to magnetic disk storage, CD-ROM, optical storage, etc.) containing computer-usable program code.

[0097] The present application is described in terms of the flowcharts and / or block diagrams of the methods, devices (systems), and computer program products according to the embodiments of the present application. It should be understood that each process and / or box in the flowchart and / or block diagram, as well as the combination of the processes and / or boxes in the flowchart and / or block diagram, can be implemented by a computer-readable storage medium 110. These computer-readable storage media 110 can be provided to a processor of a general-purpose computer, a special-purpose computer, an embedded processor, or other programmable data processing device to produce a machine, so that the program instructions 103 executed by the processor of the computer or other programmable data processing device produce a device for implementing the function specified in one process or multiple processes in the flowchart and / or one box or multiple boxes in the block diagram.

[0098] These computer-readable storage media 110 may also be stored in a computer-readable memory that can direct a computer or other programmable data processing device to operate in a specific manner, so that the program instructions 103 stored in the computer-readable storage medium 110 produce a manufactured product including an instruction device that implements the functions specified in one or more processes in the flowchart and / or one or more boxes in the block diagram.

[0099] These computer-readable storage media 110 can also be loaded onto a computer or other programmable data processing device so that a series of operating steps are executed on the computer or other programmable device to produce a computer-implemented process, so that the program instructions 103 executed on the computer or other programmable device provide steps for implementing the functions specified in one or more processes in the flowchart and / or one or more boxes in the block diagram.

[0100] Any process or method description in a flowchart or otherwise described herein may be understood to represent a module, segment or portion of code comprising one or more executable instructions for implementing the steps of a specific logical function or process, and the scope of the preferred embodiments of the present application includes alternative implementations in which functions may be performed out of the order shown or discussed, including performing functions in a substantially simultaneous manner or in the reverse order depending on the functions involved, which should be understood by those skilled in the art to which the embodiments of the present application belong.

[0101] The logic and / or steps represented in the flowchart or otherwise described herein, for example, can be considered as a sequenced list of executable instructions for implementing logical functions, and can be specifically implemented in any computer-readable medium for use by an instruction execution system, device, or apparatus (which can be a personal computer, server, network device, or other system that can fetch instructions from and execute instructions on an instruction execution system, device, or apparatus), or used in conjunction with such instruction execution systems, devices, or apparatuses. The above description is only an embodiment of the present application and does not limit the scope of the patent of the present application. Any equivalent structure or equivalent process transformation made using the contents of the present application specification and drawings, or directly or indirectly applied in other related technical fields, is also included in the scope of patent protection of the present application.

[0102] The above description is only an implementation method of the present application and does not limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made using the contents of the description and drawings of this application, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. A blood sample analyzer, wherein: The blood sample analyzer comprises: Reaction component, used for storing and transporting the sample liquid to be tested; a temperature control component, one end of which is connected to the reaction component via a pipeline, and the temperature control component is used to store the sample liquid to be tested; a sheath flow assembly, wherein the other end of the temperature control assembly is connected to the sheath flow assembly via the pipeline; when the temperature of the temperature control assembly reaches a first preset threshold, the sample liquid to be tested in the temperature control assembly is pushed into the sheath flow assembly, and the sheath flow assembly is used to obtain a pulse signal when the sample liquid to be tested passes through the detection area of ​​the sheath flow assembly; A processor is connected to the sheath flow component, and is used to calculate the counting stability of the sample liquid to be tested based on the pulse signal, and obtain a detection result of the sample liquid to be tested based on the counting stability.

2. The blood sample analyzer according to claim 1, wherein: The sample liquid to be tested in the temperature control component is pushed into the sheath flow component, so that the temperature of the sample liquid to be tested entering the sheath flow component changes with the pushing time of the sample liquid to be tested; The processor is used to calculate the particle data of the red blood cells flowing through the detection area in a first time period based on the pulse signal. The processor is also used to perform linear regression analysis on the particle data to calculate the counting stability.

3. The blood sample analyzer according to claim 2, wherein: The processor is further configured to: In response to the counting stability being greater than or equal to a second preset threshold, determining that red blood cell agglutination occurs in the sample liquid to be tested; controlling the sheath flow component to extend the detection time of the sample liquid to be tested, so as to obtain the particle data within a second time period; A detection result of the sample liquid to be tested is obtained based on the particle data in the second time period.

4. The blood sample analyzer according to claim 3, wherein: The processor is configured to use the particle data within the second time period as a detection result of the sample liquid to be tested.

5. The blood sample analyzer according to claim 3, wherein: The processor is configured to sum the particle data within the second time period and the particle data within the first time period based on a preset weight parameter, and to compensate the summation result by the particle data within the second time period to calculate a detection result of the sample liquid to be tested.

6. The blood sample analyzer according to claim 3, wherein: The processor is further configured to: In response to the counting stability being greater than a third preset threshold, selecting particle data of an extended time period away from the first time period as particle data of the second time period, the third preset threshold being greater than the second preset threshold; In response to the counting stability being less than a third preset threshold, particle data of an extended time period close to the first time period is selected as particle data of the second time period.

7. The blood sample analyzer according to claim 2, wherein: The processor is configured to perform linear regression analysis on the particle data to obtain a linear function of the particle data and the detection time of the sample liquid to be tested. The processor is further configured to use the slope of the linear function as the counting stability.

8. The blood sample analyzer according to claim 7, wherein: The processor is configured to calculate a counting result of the sample liquid to be tested when it is determined that red blood cell agglutination occurs in the sample liquid to be tested, based on the intercept of the linear function, when the sample liquid to be tested is not disaggregated.

9. The blood sample analyzer according to claim 1, wherein: The temperature control component includes a sample chamber and a heating element. One end of the sample chamber is connected to the reaction component through the pipeline, and the other end of the sample chamber is connected to the sheath flow component through the pipeline. The heating element is arranged in the sample chamber and connected to the processor. The heating element is used to heat the sample chamber.

10. The blood sample analyzer according to claim 9, wherein: The reaction component is used to mix the blood sample and the detection reagent to obtain the sample liquid to be tested. The blood sample analyzer also includes a sample pushing component, which is connected to the reaction component through the pipeline. The sample pushing component is used to push the sample liquid to be tested in the reaction component into the sample chamber. The processor is used to start the heating element so that the heating element heats the sample chamber to the first preset threshold value.

11. The blood sample analyzer according to claim 9, wherein: The reaction component is used to mix the blood sample and the detection reagent within a third time period to obtain the sample liquid to be tested, and the processor is used to start the heating element so that the heating element heats the sample chamber for a fourth time period, wherein the third time period and the fourth time period at least partially overlap.

12. The blood sample analyzer according to claim 11, wherein: The time point at which the reaction of the reaction component is completed is the same as the time point at which the heating of the sample chamber is completed.

13. The blood sample analyzer according to claim 11, wherein: The time point when the sample liquid to be tested is pushed into the sample chamber is the same as the time point when the heating of the sample chamber is completed.

14. The blood sample analyzer according to claim 9, wherein: After the heating element heats the sample chamber to the first preset threshold, the processor is used to wait for the sample liquid to be tested in the sample chamber to be depolymerized and incubated for a preset time before controlling the sample pushing component to push the sample liquid to be tested in the sample chamber to the sheath flow component.

15. The blood sample analyzer according to claim 1, wherein: The blood sample analyzer also includes a waste liquid component, which is connected to the sheath flow component through the pipeline. The sample liquid to be tested flowing through the detection area will enter the waste liquid component through the pipeline. The waste liquid component is used to collect and store the detection waste liquid generated during the detection process of the sheath flow component.

16. A method for analyzing a blood sample, wherein: include: Controlling the temperature control component to heat the sample liquid to be tested; In response to the temperature of the temperature control component reaching a first preset threshold, pushing the sample liquid to be tested in the temperature control component into the sheath flow component, so that the sample liquid to be tested passes through the detection area of ​​the sheath flow component and generates a pulse signal; The counting stability of the sample liquid to be tested is calculated based on the pulse signal, and a detection result of the sample liquid to be tested is obtained based on the counting stability.

17. The blood sample analysis method according to claim 16, wherein: The calculating the counting stability of the sample liquid to be tested based on the pulse signal, and obtaining the detection result of the sample liquid to be tested based on the counting stability, includes: calculating particle data of red blood cells flowing through the detection area within a first time period based on the pulse signal; Linear regression analysis was performed on the particle data to calculate the counting stability.

18. The blood sample analysis method according to claim 17, wherein: After the step of performing linear regression analysis on the particle data to calculate the counting stability, the blood sample analysis method further includes: In response to the counting stability being greater than a second preset threshold, determining that red blood cell agglutination occurs in the sample liquid to be tested; controlling the sheath flow component to extend the detection time of the sample liquid to be tested, so as to obtain particle data within a second time period; A detection result of the sample liquid to be tested is obtained based on the particle data in the second time period.

19. The blood sample analysis method according to claim 18, wherein: The controlling the sheath flow component to extend the detection time of the sample liquid to be tested to obtain particle data within a second time period includes: In response to the counting stability being greater than or equal to a third preset threshold, selecting particle data of an extended time period away from the first time period as particle data of the second time period; In response to the counting stability being less than the third preset threshold, selecting the particle data of the extended time period close to the first time period as the particle data of the second time period; The third preset threshold is greater than the second preset threshold.

20. A computer-readable storage medium, wherein: The computer-readable storage medium stores program instructions, and the program instructions can be executed by a processor to implement the blood sample analysis method according to any one of claims 16 to 19.

Images